Get the Stockscreener App
125.67
0.38%
0.48
After Hours:
125.67
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $125.67, with a volume of 1.61M.
It is up +0.38% in the last 24 hours and up +0.32% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$125.19
Open:
$125.71
24h Volume:
1.61M
Relative Volume:
0.22
Market Cap:
$155.92B
Revenue:
$29.05B
Net Income/Loss:
$8.11B
P/E Ratio:
19.46
EPS:
6.4563
Net Cash Flow:
$9.16B
1W Performance:
+3.55%
1M Performance:
+0.32%
6M Performance:
+17.23%
1Y Performance:
+33.76%
1-Day Range:
$125.12
$126.25
1-Week Range:
$120.93
$127.41
52-Week Range:
$88.57
$128.70
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
125.67 | 155.32B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,076.98 | 959.14B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.78 | 495.78B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.89 | 404.36B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
138.88 | 266.96B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
106.45 | 260.71B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Norden Group LLC Has $3.40 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug - Stocktwits
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise - marketscreener.com
Vontobel Holding Ltd. Acquires 394,567 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug - Investing.com
Swedbank AB Acquires 58,405 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million - Benzinga
Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Investing News Network
Gilead Sciences (GILD) to Acquire Repare Therapeutics' Key Asset - GuruFocus
Repare Therapeutics Shares Rise on $30 Million Asset Deal With Gilead - marketscreener.com
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million By Investing.com - Investing.com Canada
Gilead to buy Repare Thera’s cancer candidate for up to $30M - MSN
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment - marketscreener.com
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million - Investing.com
Repare Therapeutics Announces Acquisition Of Pol? ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration - marketscreener.com
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Bluefield Daily Telegraph
Gilead Sciences Stock (GILD) After Hours: What to Know Before the Market Opens on Dec. 24, 2025 - ts2.tech
OFI Invest Asset Management Has $42.01 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Holdings Reduced by U.S. Capital Wealth Advisors LLC - MarketBeat
Confluence Investment Management LLC Sells 16,861 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Exchange Traded Concepts LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead (GILD) Stock: Edges Slightly Lower After HSV Licensing Update - CoinCentral
Gilead Sciences (GILD) Stock After Hours on Dec. 22, 2025: What’s Moving Shares and What to Watch Before Tuesday’s Open - ts2.tech
Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs - Stocktwits
Gilead Sciences to Present at Upcoming Investor Conference - Business Wire
Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025) - ts2.tech
Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes - Benzinga
Gilead Sciences (GILD) Licenses Assembly Bio's Herpes Drug Progr - GuruFocus
UK approves Gilead’s twice-yearly HIV PrEP drug - Yahoo
Gilead pays $35M to license pair of HSV assets from Assembly Bio pact - Fierce Biotech
Gilead Sciences Picks 14-Year Company Veteran as GC - Law.com
Gilead exercises option for Assembly Bio’s herpes treatment programs - Investing.com
Gilead exercises option for Assembly Bio's herpes treatment programs - StreetInsider
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes - Business Wire
Gilead Sciences (GILD) Stock: What to Know Before the Market Opens on December 22, 2025 - ts2.tech
Gilead Sciences (GILD) Stock Week-Ahead Outlook: Pricing Deal Shockwave, HIV Pipeline Momentum, and Key Catalysts for Dec 22–26, 2025 - ts2.tech
Wedge Capital Management L L P NC Sells 59,085 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Forbes Has Listed Gilead as One of America’s Best Employers for Diversity - CSRwire
Gilead (GILD): Revisiting Valuation After HIV Wins and New U.S. Drug Pricing Agreement - simplywall.st
Portfolio Recap: Will Gilead Sciences Inc. stock outperform value stocksProfit Target & Capital Protection Trading Alerts - ulpravda.ru
Key facts: Gilead shares up 3.3% on positive HIV trial; drug prices to drop - TradingView — Track All Markets
Gilead Sciences (NASDAQ:GILD) Cut to "Buy" at Wall Street Zen - MarketBeat
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal - Benzinga
Gilead Sciences Stock (GILD) After Hours on Dec. 19, 2025: TrumpRx Pricing Deal, UK Lenacapavir Approval, and What to Watch Before the Next Market Open - ts2.tech
Why Gilead Sciences (GILD) Stock Is Up Today - The Globe and Mail
Gilead agrees to lower drug prices in U.S. under Trump administration deal - Investing.com Nigeria
Gilead Sciences Signs Deal With US Government to Lower Drug Costs - marketscreener.com
Gilead (GILD) Strikes Deal to Cut Drug Costs With U.S. Governmen - GuruFocus
GILEAD reaches three-year pricing agreement with US government - StreetInsider
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans - Business Wire
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gilead Sciences Inc Stock (GILD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Commercial Officer |
Dec 15 '25 |
Sale |
122.00 |
3,000 |
366,000 |
106,221 |
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):